A
Andreas Pettersson
Researcher at Karolinska Institutet
Publications - 84
Citations - 3677
Andreas Pettersson is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 30, co-authored 77 publications receiving 3189 citations. Previous affiliations of Andreas Pettersson include Harvard University & Cancer Epidemiology Unit.
Papers
More filters
Journal ArticleDOI
Age at Surgery for Undescended Testis and Risk of Testicular Cancer
TL;DR: Treatment for undescended testis before puberty decreases the risk of testicular cancer, and the effect of age at orchiopexy on the risk in the cohort was similar in comparisons within the cohort.
Journal ArticleDOI
A Computed Tomographic Scan–Derived Customized Surgical Template and Fixed Prosthesis for Flapless Surgery and Immediate Loading of Implants in Fully Edentulous Maxillae: A Prospective Multicenter Study
Daniel van Steenberghe,Roland Glauser,Ulf Blomback,Matts Andersson,Filip Schutyser,Andreas Pettersson,Inger Wendelhag +6 more
TL;DR: The present prospective multicenter study indicates that the prefabrication, on the basis of models derived from three-dimensional oral implant planning software, of both surgical templates for flapless surgery and dental prostheses for immediate loading is a very reliable treatment option.
Journal ArticleDOI
The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: a Cohort Study and Meta-analysis
Andreas Pettersson,Rebecca E. Graff,Scott R. Bauer,Michael J. Pitt,Rosina T. Lis,Edward C. Stack,Neil E. Martin,Lauren Kunz,Kathryn L. Penney,Azra H. Ligon,Catherine A. Suppan,Richard Flavin,Howard D. Sesso,Jennifer R. Rider,Christopher Sweeney,Meir J. Stampfer,Michelangelo Fiorentino,Philip W. Kantoff,Martin G. Sanda,Edward Giovannucci,Eric L. Ding,Massimo Loda,Lorelei A. Mucci +22 more
TL;DR: It is suggested that TMPRSS2:ERG, or ERG overexpression, is associated with tumor stage but does not strongly predict recurrence or mortality among men treated with radical prostatectomy.
Journal ArticleDOI
Mammographic Density Phenotypes and Risk of Breast Cancer: A Meta-analysis
Andreas Pettersson,Rebecca E. Graff,Giske Ursin,Isabel dos Santos Silva,Valerie McCormack,Laura Baglietto,Laura Baglietto,Celine M. Vachon,Marije F. Bakker,Marije F. Bakker,Graham G. Giles,Graham G. Giles,Graham G. Giles,Kee Seng Chia,Kamila Czene,Louise Eriksson,Per Hall,Mikael Hartman,Ruth M. L. Warren,Gregory Hislop,Anna M. Chiarelli,John L. Hopper,Kavitha Krishnan,Kavitha Krishnan,Jingmei Li,Qing Li,Ian S Pagano,Bernard Rosner,Chia Siong Wong,Christopher G. Scott,Jennifer Stone,Gertraud Maskarinec,Norman F. Boyd,Carla H. van Gils,Carla H. van Gils,Rulla M. Tamimi +35 more
TL;DR: It is suggested that percentage dense area is a stronger breast cancer risk factor than absolute dense area, but it is unclear whether the association is independent ofabsolute dense area.
Journal ArticleDOI
A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer
Thomas U. Ahearn,Andreas Pettersson,Andreas Pettersson,Ericka M. Ebot,Travis Gerke,Rebecca E. Graff,Rebecca E. Graff,Carlos L. Morais,Jessica Hicks,Kathryn M. Wilson,Jennifer R. Rider,Howard D. Sesso,Michelangelo Fiorentino,Richard Flavin,Stephen P. Finn,Edward Giovannucci,Massimo Loda,Meir J. Stampfer,Angelo M. De Marzo,Lorelei A. Mucci,Tamara L. Lotan +20 more
TL;DR: PTEN loss is independently associated with increased risk of lethal progression, particularly in the ERG fusion-negative subgroup, and these validated and inexpensive IHC assays may be useful for risk stratification in prostate cancer.